by Andrea Lobo | Feb 9, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech that’s being tested in people with relapsing/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, two aggressive forms of...
by Marisa Wexler, MS | Feb 6, 2026 | Myeloma News
A first-in-human clinical trial will launch in the coming months to test GTB-5550, an immune therapy from GT Biopharma that’s designed to treat various types of cancer, including pancreatic cancer, in patients whose tumors express a protein marker called B7-H3. GT...
by MM360 Staff | Feb 6, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Feb 6, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Feb 6, 2026 | Uncategorized
Source: CURE articles Post Content Read More
